Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder


Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey

Received August 17, 2016; accepted December 5, 2016

ABSTRACT

Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β3-adrenergic receptors (β3-ARs) and their potential as therapeutics is just emerging. In this manuscript, we characterized the pharmacology of a novel β3AR agonist vibegron (MK-4618, KRP-114V) and explored mechanistic interactions of β3AR agonism and muscarinic antagonism in urinary bladder function. Vibegron is a potent, selective full β3AR agonist across species, and it dose dependently increased bladder capacity, decreased micturition pressure, and increased bladder compliance in rhesus monkeys. The relaxation effect of vibegron was enhanced when combined with muscarinic antagonists, but differentially influenced by muscarinic receptor subtype selectivity. The effect was greater when vibegron was co-administered with tolterodine, a nonselective antagonist, compared with coadministration with darifenacin, a selective M3 antagonist. Furthermore, a synergistic effect for bladder strip relaxation was observed with the combination of a β3-AR agonist and tolterodine in contrast to simple additivity with darifenacin. To determine expression in rhesus bladder, we employed a novel β3AR agonist probe, [3H]MRL-037, that selectively labels β3 receptors in both urothelium and detrusor smooth muscle. Vibegron administration caused a dose-dependent increase in circulating glycerol and fatty acid levels in rhesus and rat in vivo, suggesting these circulating lipids can be surrogate biomarkers. The translation of our observation to the clinic has yet to be determined, but the combination of β3AR agonists with M2/M3 antimuscarinics has the potential to redefine the standard of care for the pharmacological treatment of overactive bladder.
ATP acts on P2X-purine receptors, particularly under pathologic conditions (Andersson, 2015), in the detrusor to initiate bladder contraction.

Disruption of this coordinated communication can result in a symptom complex characterized by urinary urgency, with or without urgency-associated urinary incontinence, referred to as overactive bladder (OAB) (Abrams et al., 2002). It is estimated that 12–23% of the general population exhibits symptoms of OAB, with a significant degradation in quality of life (Irwin et al., 2006; Coyne et al., 2011). Management of OAB is typically a multimodal approach, employing both nonpharmacological and pharmacological treatment paradigms. When nonpharmacological approaches (i.e., lifestyle and dietary modification) are ineffective, antimuscarinics are the first-line pharmacological treatment, representing the most commonly prescribed drug therapy (Abrams and Andersson, 2007). Although antimuscarinics have been demonstrated to improve urgency and decrease frequency of micturition and urge incontinence, blockade of the M3 muscarinic receptor can lead to adverse effects (AEs) such as dry mouth and constipation (Abrams and Andersson, 2007). These AEs contribute to a high discontinuation rate, resulting in significant unmet medical need for a pharmacological treatment of OAB with an improved AE profile while maintaining or exceeding the efficacy of antimuscarinics (Chapple et al., 2008).

β3AR activation in the bladder represents the most relevant mechanism to increase bladder capacity without affecting bladder contraction. Initial studies in isolated human bladder using nonselective βAR agonists such as isoproterenol demonstrated a pronounced bladder relaxation (Anderson, 1993). Subsequent studies using selective β3AR agonists in isolated human detrusor muscle strips determined that the observed relaxation was due to activation of β3AR (Rouget et al., 2014; Gillespie et al., 2015; Michel and Korstanje, 2016). Given increasing evidence for β3AR activation as a treatment of OAB, efforts to discover or repurpose potent and selective β3AR agonists were initiated in recent years (Furuta et al., 2006; Drake, 2008). Subsequently, four selective β3AR agonists, mirabegron (Tyagi and Tyagi, 2010), rizobegron (Maruyama et al., 2012), solabegron (Ohlstein et al., 2012), and vibegron (Edmondson et al., 2016) entered clinical trials for treatment of OAB, with published clinical data available for both mirabegron and solabegron. In 2012, mirabegron demonstrated significant efficacy in reducing micturition frequency, urgency incontinence, and increasing mean volume per micturition in patients with OAB (Chapple et al., 2014) and subsequently received regulatory approval.

Herein, we describe the pharmacological characterization of the novel β3AR agonist vibegron (MK-4618, KRP-114V) (Edmondson et al., 2016) currently under clinical development for OAB. In addition, we describe the mechanistic interaction of β3AR agonists and antimuscarinics in bladder function and we propose an optimal combination of these mechanisms in the treatment of OAB.

Materials and Methods

Subjects. All procedures related to the use of animals were approved by the Institutional Animal Care and Use Committee at Merck Research Laboratories (Rahway, NJ) and conform to the NIH Guide for the Care and Use of Laboratory Animals (8th edition, 2011). A total of 16 adult female rhesus monkeys (Macaca mulatta) weighing 5 to 7 kg and 4–7 years of age were used. Animals were either paired or individually housed in temperature/humidity controlled rooms on a 12-hour light/12-hour dark cycle and fed standard laboratory chow (Tekland, Harlan Laboratories, Indianapolis, IN) supplemented with fresh fruit and vegetables with ad libitum water. A total of 81 male adult Sprague-Dawley rats weighing 250 to 350 g (Charles River, Wilmington, MA) were housed in temperature and light-controlled (12-hour light/12-hour dark cycle) cages, fed standard laboratory chow (Diet 7012, Harlan) and water ad libitum.

Reagents. Vibegron (65S-N-[4-((25S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]-methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropropyrolo[1,2-alpyrimidine-4-carboxamide), MRL-037 ((R)-2-amino-N-4-((25S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]-methyl)phenyl]-5,6-dihydro-4H-cyclopentadi[thiazole-4-carboxamide), and [3H]MRL-037 ((R)-2-amino-N-4-((25S,5R)-5-[(R)-hydroxy(phenyl)-3,5-tetrahydropropyrrolidin-2-yl]-methyl)phenyl]-2,6-di-hydro-4H-cyclopentadi[thiazole-4-carboxamide) were synthesized by the Discovery Chemistry Department (Merck Research Laboratories) as previously described (Moyes et al., 2014; Edmondson et al., 2016; Supplemental Fig. S1). CL316,243 diisodium 5-[(2R)-2-[(2R)-2-[(3-chlorophenyl)-2-hydroxyethylaminol]-1,3-benzenoxiole-2,2-dicarboxylate), oxybutynin chloride, and methoctramine hydrate were purchased from Sigma-Aldrich (St. Louis, MO). Tolterodine tartrate and darifenacin hydrobromide were purchased from Toronto Research Chemicals (North York, Canada) and AK Scientific (Union City, CA), respectively.

Autoradiography of Bladder Sections with [3H]MRL-037—Ex Vivo Receptor Occupancy Assay. Rhesus monkeys were anesthetized with an intramuscular injection of 5 mg/kg Telazol (Zoetis, Parsippany, NJ) or ketamine HCl (20 mg/kg) followed by a lethal dose of a euthanasia drug (i.e., Euthasol; Virbac AH Inc., Fort Worth, TX). The bladder was then surgically removed and cut into 20-μm-thick sections, collected on superfrost/plus slides using a rapid sectioning cryostat (Leica CM1900), and then air dried for 30–60 minutes at room temperature. After marking boundaries around the section with pan-pep, the tissue was covered with 600–1000 μl of binding buffer (50 mM Tris-HCl, 2 mM MgCl2, 1 mM CaCl2, 5 mM KCl, 0.1% bovine serum albumin) containing 50 nM of [3H]MRL-037 (specific activity of 30-50 Ci/mmol; Merck Research Laboratories) without or with 10 μM of cold MRL-037 for nonspecific binding for 25 minutes. After incubation, the slides were washed for 4 minutes with ice-cold binding buffer containing 0.05% Triton X-100 for total of six times and then soaked twice into in 30 ml of ice-cold buffer with 0.05% Triton X-100 in a staining jar for 4 minutes each wash, followed by dipping the slides three times in ice-cold water. Slide were dried and exposed to Kodak MR-2 895 2855 Sigma Kodak BioMax MR film (Cat # 2530400-50EA) for 5 days. Adjacent bladder sections were stained with hematoxylin and eosin for histology following standard protocol (Longnecker, 1966).

In Vitro Potency and Selectivity of Vibegron on β-Adrenergic Receptors. The ability of vibegron to activate the human, rhesus, rat, and dog β1, β2, and β3 AR was measured using CHO cell lines stably expressing the appropriate adrenergic receptor (Candelore et al., 1999). For β3AR, the human cell line used expressed β3 at levels similar to those observed in human detrusor muscle (Supplemental Fig. S2). To quantify the amount of released cAMP after β-AR activation, the LANCE cAMP kit (Perkin Elmer, Shelton, CT), a time-resolved fluorescence resonance energy transfer immunoassay, was used. Compounds were serially diluted in DMSO and an aliquot added to either 384-well or 96-well micro titer plates in assay buffer (5 mM HEPES, 0.1% bovine serum albumin in Hank’s balanced salt solution). The reaction was initiated by the addition of 6000 cells per well in assay buffer that also contained a cAMP-specific antibody labeled with Alexa Fluor 647 and a phosphodiesterase inhibitor (IBMX, Sigma). To examine serum-shifted potency, efficacy was evaluated using an assay buffer containing 40% pooled human, rhesus, or rat serum. Because of a smaller assay window with serum compared with the buffer assay, the number of cells was increased to 10,000 per well. After 30-minute incubation at room temperature, the cells were lysed by the addition of...
LANCE detection buffer containing a europium-labeled cAMP tracer. Fluorescence was measured after 1-hour incubation at room temperature using a PE Envision reader, exciting at 340 nm and measuring emission at 615 and 665 nm. For each assay, a cAMP standard curve was included and used to convert fluorescence readings directly to cAMP amounts. Values were normalized to a known full agonist (isoproterenol), and the EC_{50} and percent maximum activation was then determined.

**Isometric Detrusor Muscle Tension Recordings.** Rats were euthanized with CO\textsubscript{2} and the entire bladder was surgically removed and the mucosa was left intact. The bladder was then placed in a bath of Krebs solution (113 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl\textsubscript{2}, 1.2 mM MgSO\textsubscript{4}, 25 mM NaHCO\textsubscript{3}, 1.2 mM KH\textsubscript{2}PO\textsubscript{4}, and 1.5 mM glucose). The bladder dome was dissected in four approximately equal pieces of about 6 mm × 3 mm. Each strip was placed in a warmed (37°C) organ bath (25 ml) containing oxygenated (95% O\textsubscript{2} at the bladder base. Another two lumens were connected to a pressure transducer and an infusion pump for intravesical pressure measurement and intravesical saline infusion, respectively. The intravesical pressure was recorded using a multiple channel data acquisition system (PowerLab, AD Instruments) at a sampling rate of 20 Hz. After confirming bladder emptiness by ultrasonography, saline was intravesically infused at 15 ml/min. Saline infusion was discontinued when a rapid increase in the intravesical pressure due to the micturition reflex was observed. After two baseline cystometry readings, a compound was intravenously dosed using a rising dose paradigm, with a cystometry measurement performed 10 minutes after each dose. Blood samples were taken for measurements of plasma compound levels and serum glycerol/free fatty acid (FFA) levels right after each cystometry. The following cystometric parameters were obtained from each cystometry: bladder capacity (duration of bladder filling multiplied by intravesical infusion rate), maximum micturition pressure (the pressure reading of the first peak in intravesical pressure driven by the micturition reflex), and bladder compliance (inverse of average slope of intravesical pressure during filling phase). The changes from baseline were calculated and compared with the values in the vehicle-treated group or baseline values.

**Statistical Analysis.** Data are presented as arithmetic mean ± S.D., S.E.M., or geometric mean with confidence intervals (CI) except where indicated. The mean values were compared with two-way analysis of variance with Bonferroni’s post hoc test or one-way analysis of variance with Dunnett’s multiple comparison test. A probability value less than or equal to 0.05 was considered significant.

### Results

**Potency of Vibegron at β-Adrenergic Receptors across Species.** Vibegron (Fig. 1A) potently activates human β\textsubscript{3}AR and increases cAMP levels, with an EC\textsubscript{50} of 1.1 nM and 87% activation relative to isoproterenol (Emdonson et al., 2016). Vibegron is also highly selective over β\textsubscript{1}AR and β\textsubscript{2}AR versus β\textsubscript{3}AR across multiple species, demonstrating >9000-fold selectivity for activation of β\textsubscript{3}AR over β\textsubscript{1}AR or β\textsubscript{2}AR in cell based in vitro functional assays (Table 1). A small serum shift was observed in the presence of 40% human serum (EC_{50} 1.7 nM; Fig. 1B). The small effect of serum was also observed for rat and rhesus β\textsubscript{3}AR, consistent with the low noncovalent plasma protein binding (Emdonson et al., 2016).

**Localization of β\textsubscript{3}AR in Rhesus Bladder with a Labeled β3AR Agonist.** To determine expression of β\textsubscript{3}AR in rhesus tissue, we used a radiolabeled agonist of β\textsubscript{3}AR, [\textsuperscript{3}H]MRL-037 (Fig. 2A; Supplementary Fig. S1), a pan-species potent and selective β\textsubscript{3}AR agonist (Moyses et al., 2014), in tissue autoradiography experiments. This compound is a potent β\textsubscript{3}AR agonist across multiple species with no activity at β\textsubscript{1} or β\textsubscript{2} and with physiochemical properties that make it a suitable tracer for localizing β\textsubscript{3}AR expression in tissue. Similar to the staining pattern in human tissue observed with immunohistochemistry (Limberg et al., 2010), clear staining of the urothelium was observed in rhesus bladder using [\textsuperscript{3}H]MRL-037 (Fig. 2, B and C). Staining of human bladder tissue with [\textsuperscript{3}H]MRL-037 produced a similar pattern.
cystometry model. As investigated in the rat bladder across concentrations up to 10 mg/kg i.v. in the rhesus similar potency (Table 1). Accordingly, vibegron was evaluated vibegron activates both human and rhesus monkey similarities of the lower urinary tract to humans. Additionally, evaluation of vibegron because of physiologic and anatomic macodynamic model offers advantages for pharmacological vibegron to nonhuman primates. A nonhuman primate phar-lipolysis readouts. We sought to extend the evaluation of comparison with activity in adipose tissue as measured by (Edmondson et al., 2016), measured by cystometry, and the activity of vibegron in a rat bladder hyperactivity model (Fig. 3A). The maximum bladder capacity increase induced by vibegron was 156% of baseline value, which is comparable to maximum effect with antimuscarinics (Nagabukuro et al., 2011). Micturition pressure was signifi-cantly decreased at 0.3 and 3 mg/kg (Fig. 3B). Bladder compliance was increased at doses greater than 0.1 mg/kg (Fig. 3C). Vibegron also increased serum glycerol and FFA levels in a dose-dependent manner (Fig. 3, D and E). Concentra-tion response curves for bladder capacity and serum glycerol closely overlapped (see Table 2 for vibegron plasma levels), where the EC$_{50}$ value in increasing bladder capacity was 2.9 nM in total plasma and 1.5 nM at unbound levels; for increasing serum glycerol, the EC$_{50}$ value was 9.9 nM in total plasma and 5.0 nM at unbound levels (Edmondson et al., 2016).

### Dose-dependent Effects of Vibegron in Urodynamic Parameters in Rhesus Monkeys

We previously reported the activity of vibegron in a rat bladder hyperactivity model (Edmondson et al., 2016), measured by cystometry, and the comparison with activity in adipose tissue as measured by lipolysis readouts. We sought to extend the evaluation of vibegron to nonhuman primates. A nonhuman primate pharmacodynamic model offers advantages for pharmacological evaluation of vibegron because of physiologic and anatomic similarities of the lower urinary tract to humans. Additionally, vibegron activates both human and rhesus monkey $\beta_3$AR at a similar potency (Table 1). Accordingly, vibegron was evaluated across concentrations up to 10 mg/kg i.v. in the rhesus cystometry model. As investigated in the rat bladder hyperactivity model, a relationship between indices of bladder function and target engagement markers of acute $\beta_3$AR stimulation in adipose tissue, i.e., circulating glycerol increase in rhesus monkeys, was also examined. Baseline values of urodynamic parameters in vehicle- and vibegron-treated animals are as follows: bladder capacity, 156.8 ± 21.6 ml (vehicle), 123.7 ± 10.7 ml (vibegron); micturition pressure, 36.7 ± 1.6 cm H$_2$O (vehicle), 35.5 ± 2.8 cm H$_2$O (vibegron); bladder compliance, 15.0 ± 2.2 ml/cm H$_2$O (vehicle), 16.6 ± 2.8 ml/cm H$_2$O (vibegron). As in the previous study (Nagabukuro et al., 2011), vehicle had no statistically significant effect on any of parameters. Vibegron increased bladder capacity in a dose-dependent manner (Fig. 3A). The maximum bladder capacity increase induced by vibegron was 156% of baseline value, which is comparable to maximum effect with antimuscarinics (Nagabukuro et al., 2011). Micturition pressure was significantly decreased at 0.3 and 3 mg/kg (Fig. 3B). Bladder compliance was increased at doses greater than 0.1 mg/kg (Fig. 3C). Vibegron also increased serum glycerol and FFA levels in a dose-dependent manner (Fig. 3, D and E). Concentration response curves for bladder capacity and serum glycerol closely overlapped (see Table 2 for vibegron plasma levels), where the EC$_{50}$ value in increasing bladder capacity was 2.9 nM in total plasma and 1.5 nM at unbound levels; for increasing serum glycerol, the EC$_{50}$ value was 9.9 nM in total plasma and 5.0 nM at unbound levels (Edmondson et al., 2016).

### Effect of Combined Treatments of a $\beta_3$AR Agonist with Antimuscarinics in Isolated Detrusor Muscle

CL316,243 and all antimuscarinics oxybutynin, tolterodine and darifenacin, inhibited the EFS-induced isolated detrusor muscle contractions in a concentration-dependent manner (Fig. 4, A and B). Unlike oxybutynin, vibegron also depressed the spontaneous contractile activity. Concentrations that induced 25% inhibition (IC$_{25}$) were used to determine combination ratios and for isobologram analyses (Table 3). CL316,243 was cotreated with tolterodine, oxybutynin, or darifenacin at a fixed combination ratio. Isobologram analyses are shown in Fig. 5. Based on the CI criteria (see Materials and Methods), all combinations were synergistic, but with different degrees of synergism: tolterodine >

### TABLE 1

Potency and selectivity of vibegron at human, rhesus, rat, and dog $\beta_1$, $\beta_2$, and $\beta_3$AR

<table>
<thead>
<tr>
<th>AR Subtype</th>
<th>Species</th>
<th>EC$_{50}$ (CI)</th>
<th>EC$_{50}$, nM w/ 40% Serum (CI)</th>
<th>% activation</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\beta_1$</td>
<td>Human</td>
<td>1.0 (1.5,0.71); 84%</td>
<td>1.5 (2.3, 1.0); 102%</td>
<td></td>
</tr>
<tr>
<td>$\beta_1$</td>
<td>Human</td>
<td>&gt;10,000; 5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\beta_2$</td>
<td>Human</td>
<td>&gt;10,000; 7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\beta_3$</td>
<td>Rhesus Monkey</td>
<td>0.52 (0.81, 0.30); 108%</td>
<td>5.5 (12, 2.6); 98%</td>
<td></td>
</tr>
<tr>
<td>$\beta_3$</td>
<td>Rhesus Monkey</td>
<td>&gt;10,000; 4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\beta_3$</td>
<td>Rat</td>
<td>&gt;10,000; 0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\beta_3$</td>
<td>Rat</td>
<td>81 (119,55); 83%</td>
<td>118 (161,85); 89%</td>
<td></td>
</tr>
<tr>
<td>$\beta_3$</td>
<td>Dog</td>
<td>10 (15, 7.1); 82%</td>
<td></td>
<td>N.D.</td>
</tr>
<tr>
<td>$\beta_1$</td>
<td>Dog</td>
<td>&gt;10000; 2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\beta_2$</td>
<td>Dog</td>
<td>&gt;10,000; 1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.D., not determined.
Antimuscarinics in Rhesus Monkeys. To extend our bladder relaxation in rhesus only when used at high doses. Increase compared with each compound alone, with effects of vibegron and tolterodine showed a greater bladder capacity et al., 2011) as we carried out the study with exactly the same darifenacin from our previous publication (Nagabukuro monkeys. We used monotherapy data for tolterodine and darifenacin were evaluated in the cystometry model in rhesus of vibegron and two antimuscarinic agents tolterodine and CL316,243 and darifenacin exhibited much more robust combination. As shown in Fig. 5D, combination with cant change in isobologram for the darifenacin and CL316,243 (data not shown). However, methoctramine caused a signifi-

Effect of Combined Treatments of Vibegron and Antimuscarinics in Rhesus Monkeys. To extend our findings of combination therapy with vibegron, cotreatments of vibegron and two antimuscarinic agents tolterodine and darifenacin were evaluated in the cystometry model in rhesus monkeys. We used monotherapy data for tolterodine and darifenacin from our previous publication (Nagabukuro et al., 2011) as we carried out the study with exactly the same methods and within similar timeframe. All dose combinations of vibegron and tolterodine showed a greater bladder capacity increase compared with each compound alone, with effects that are greater than additive at low doses (Table 4). In contrast, addition of darifenacin to vibegron induced greater bladder relaxation in rhesus only when used at high doses.

Discussion
Given the questionable selectivity of antibodies for staining of β3AR in rhesus monkeys, we turned to a more novel approach of identifying β3AR expression in the urinary bladder of this species—use of a selective β3 agonist radioligand, MRL-037—to label β3AR expressing cells in the urinary bladder. From our in vitro characterization of MRL-037, this compound is extremely selective for β3 across several species, including rhesus monkeys. Using autoradiography of bladder sections incubated with [3H]MRL-037, β3AR expression was detected in urothelium. Although less intense, β3AR expression was detected in detrusor as well, similar to what was previously observed in human bladder, where β3AR expression appears to be more intense in the urothelium compared with the detrusor (Limberg et al., 2010). The potency and selectivity of MRL-037 across several species provides for a unique means to directly compare and quantify β3AR expression across multiple species using a single tool. In addition, MRL-037 could be employed to determine ex vivo receptor occupancy, providing a means to directly correlate β3AR target engagement in the bladder to efficacy.

We observed staining for β3AR in the urothelium of human and rhesus monkey. Given our data, along with previously published observations (Limberg et al., 2010; Kullmann et al., 2011; Otsuka et al., 2013), β3AR is expressed in both the detrusor muscle and bladder urothelium across multiple species. The exact role of β3AR in the urothelium and its contribution to the observed efficacy of β3AR agonists in treating OAB is unknown, but there is mounting evidence that β3ARs in the urothelium likely contribute either directly or indirectly to the observed clinical effects of β3AR agonists. Our demonstration of agonist binding to urothelium and the previously reported β3AR agonist-induced functionality in an immortalized human urothelium cell line (Harmon et al., 2005) infer that β3AR agonists can have a direct effect on activating cells within the urothelium. However, the functional role of β3ARs in the urothelium has not been well documented. Masunaga et al. (2010) and Kullmann et al. (2011) showed that in porcine and rat bladder strips relaxation of the detrusor muscle by nonselective βAR and selective β3AR stimulation occurs to the same extent with or without urothelium. Alternatively, others reported that the oxybutynin > darifenacin (Fig. 5). The M2 selective antagonist methoctramine caused only marginal inhibition of the EFS-induced detrusor contraction (0.003–10 μM; Supplemental Fig. S4). Given the potency of methoctramine at muscarinic receptor subtypes other than M2 (Kᵢ, ~1 μM), significant inhibition at the higher concentrations was expected. But at least in the current experimental setting, there was less than 25% inhibition of EFS-induced isolated detrusor contraction. In addition, pretreatment of methoctramine (1 μM) did not affect CL316,243-induced inhibition of detrusor contraction (data not shown). However, methoctramine caused a significant change in isobologram for the darifenacin and CL316,243 combination. As shown in Fig. 5D, combination with CL316,243 and darifenacin exhibited much more robust synergism with a pretreatment of methoctramine (CI, 0.16) compared with the same 1 μM.

Fig. 2. MRL β3AR Agonist [3H]MRL-037 (A) is a potent full agonist at the human (EC50 = 0.12 nM), rhesus (EC50 = 0.12 nM), rat (EC50 = 1.0 nM), and dog (EC50 = 0.19 nM) β3ARs with no affinity for the β1 and β2 subtypes (EC50 and IC50 > 10 μM all species). Comparison of binding of [3H]MRL-037 to histologic staining in rhesus bladder tissue: (B) autoradiography after incubation of bladder with 50 nM [3H]MRL-037 and an excess of unlabeled MRL-037 was performed followed by autoradiography. Arrows indicate regions of intact urothelium. Adjacent sections of bladder are shown. Data are representative of three studies.
presence of urothelium diminishes nonselective βAR-induced relaxation of isolated human detrusor muscle (Otsuka et al., 2008; Propping et al., 2013). By using subtype selective βAR antagonists, β2AR was suggested to be involved in this urothelial effect, whereas β3AR directly mediates the relaxation of human detrusor, and its involvement did not differ with or without urothelium (Propping et al., 2013).

Medicinal chemistry efforts at optimizing the potency, selectivity, and pharmacokinetic properties of a series of pyrrolidine derived amides led to the discovery of vibegron, which is currently in late stage clinical trials for OAB (Edmondson et al., 2016). In two different preclinical species, vibegron causes dose-dependent relaxation of urinary bladder, resulting in an increase in bladder capacity and a decrease in micturition pressure. These pharmacodynamic effects in the lower urinary tract accompany an increase in circulating glycerol and FFA, indicating the potential use of β3AR activation in adipose tissue as a surrogate pharmacodynamic/target engagement readout for urinary bladder. Interpretation of the relative pharmacodynamics effects of β3AR activation in adipose tissue to bladder must be done with care when translating across organs and species. In rhesus cystometry studies,

Fig. 3. Effect of vibegron on the bladder capacity (A), maximum intravesical pressure (B), bladder compliance (C), serum glycerol (D), and nonesterified free fatty acids (NEFFA) (E) in anesthetized rhesus monkeys. Values represent mean ± S.D. of value or of percentage of baseline values as indicated. N = 6. *P < 0.05, **P < 0.01 versus baseline values, repeated-measures analysis of variance; #P < 0.05, ##P < 0.01, versus vehicle-treated group, Dunnett’s multiple comparison test. a, Not applicable for statistical analyses because of lack of data from one animal (N = 5).

TABLE 2
Plasma levels of vibegron in anesthetized rhesus monkeys
Values represent mean ± S.D. (N = 4–6).

<table>
<thead>
<tr>
<th>Plasma Vibegron Level</th>
<th>nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.003 mg/kg</td>
<td>0.5 ± 0.4</td>
</tr>
<tr>
<td>0.01 mg/kg</td>
<td>1.2 ± 0.1</td>
</tr>
<tr>
<td>0.03 mg/kg</td>
<td>3.0 ± 0.9</td>
</tr>
<tr>
<td>0.1 mg/kg</td>
<td>13.1 ± 3.6</td>
</tr>
<tr>
<td>0.3 mg/kg</td>
<td>43.4 ± 15.4</td>
</tr>
<tr>
<td>1 mg/kg</td>
<td>128.5 ± 27.9</td>
</tr>
<tr>
<td>3 mg/kg</td>
<td>553.6 ± 144.0</td>
</tr>
</tbody>
</table>
elevated levels of serum glycerol correlated with β3AR-mediated increases in bladder capacity, with the two readouts of β3AR activation closely overlapping each other. In rats, although decreases in micturition pressure are accompanied by an increase in circulating glycerol levels, we observed elevated glycerol levels in the absence of any effect on bladder compliance, suggesting that rat adipose is the more sensitive tissue to β3AR activation relative to bladder (Edmondson et al., 2016).

Although β3AR is also involved in lipolysis in human adipose (Bordicchia et al., 2014), the effects of β3AR activation in rat adipose appear to be much more profound compared with that observed in human adipose, and this was noted in the early clinical programs looking at β3AR agonists for obesity (Ursino et al., 2009). Chronic administration of β3AR agonists in obese rats results in weight loss without changes in food intake due to increased energy expenditures (Ursino et al., 2009; Cernecka et al., 2014), but no such effect is observed in humans (Arch, 2008). β3AR is the predominant subtype in both white and brown adipose tissue in rats, whereas in humans and rhesus monkeys only in brown adipose does β3AR predominate, with little β3AR expression in white adipose (Candelore et al., 1999). This increased expression of β3AR in rat adipose and the more pronounced effect on metabolism may explain our observation of differential sensitivity to β3AR agonists in rat adipose versus rat bladder. Alternatively, the difference may not be in tissue sensitivity but may reflect physiologic differences in the rodent versus primate lower urinary tract, such that β3AR agonists may play more active of a role in adipose tissue in rats versus primates.

Our studies combining a β3AR agonist with antimuscarinics resulted in enhanced bladder relaxation in both rats and rhesus monkeys, with greater synergism when both muscarinic M2 and M3 subtypes were blocked compared with selective blockade of the M3 subtype. Although M3 appears to be the predominant muscarinic subtype in mediating contractile responses in bladder detrusor muscle, the role of M2 receptors in bladder is less certain despite it being the more highly expressed subtype (>90% in rat bladder) (Wang et al., 1995). It has been suggested that the M2 subtype contributes to bladder relaxation but in a more indirect role through the enhancement of M3-mediated contractions and through inhibition of bladder relaxation (Ehlert et al., 2005; Matsumoto et al., 2012). The inhibition of bladder relaxation mediated by M2 activation is thought to occur via the inhibition of adenyl cyclase (the M2 receptor subtype is Gi-coupled), which opposes the increase in cAMP elicited by activation of β3AR (Matsui et al., 2003; Ehlert et al., 2007). In the absence of an M2 response, forskolin and isoproterenol exhibit a greater relaxant activity compared with conditions under which M2 is active (Matsui et al., 2003; Ehlert et al., 2007). Inhibition of M2 activity would have a direct impact on the effects of β3AR activation by increasing cAMP levels and would therefore provide greater relaxation mediated through β3AR activation, which is in accordance with our findings in this study. Recently, Furuta et al. (2016) reported that in conscious female rats, the combination therapy of a β3AR agonist and muscarinic M3 antagonists was more effective in increasing bladder capacity than monotherapy and that M2 antagonism had no impact on the effect of a β3AR agonist. We also confirmed that simple M2 antagonism did not influence β3AR agonist-induced relaxation of rat bladder strips. Additionally, muscarinic receptor subtype contribution to bladder

![Fig. 4. Effects of concentrations of a β3AR agonist CL316,243 and muscarinic antagonists on EFS-induced contraction of rat bladder strips.](Image)

(A) Representative recordings of isometric tension of bladder strips during the course of cumulative treatment of vehicle, CL316,243, and oxybutynin. (B) Dose titration of CL316,243, tolterodine, oxybutynin, and darifenacin. N = 7 or 8.

<table>
<thead>
<tr>
<th>Drug</th>
<th>IC50 (nM)</th>
<th>Upper 95% CI</th>
<th>Lower 95% CI</th>
<th>Combination Index with CL316,243</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL316,243</td>
<td>2.86</td>
<td>5.91</td>
<td>1.18</td>
<td>—</td>
</tr>
<tr>
<td>Tolterodine</td>
<td>4.71</td>
<td>11.68</td>
<td>1.89</td>
<td>0.21</td>
</tr>
<tr>
<td>Oxybutynin</td>
<td>22.28</td>
<td>68.45</td>
<td>8.86</td>
<td>0.50</td>
</tr>
<tr>
<td>Darifenacin</td>
<td>5.84</td>
<td>11.29</td>
<td>3.07</td>
<td>0.71</td>
</tr>
</tbody>
</table>

TABLE 3
Potency of CL316,243, tolterodine, oxybutynin, and darifenacin in inhibiting EFS-induced contraction of rat bladder strips and combination index of each antimuscarinic with CL316,243.
function may differ between species. In nonhuman primates, muscarinic subtypes other than M3 appear to contribute more to bladder storage functions than rodents (Nagabukuro et al., 2011). Multiple clinical studies have demonstrated additional benefits by combining solifenacin and mirabegron (Abrams et al., 2015; De Nunzio, et al., 2015; Kosilov et al., 2015). Because solifenacin is more M3 selective compared with tolterodine and oxybutynin (Ohtake et al., 2007), it may be possible to improve further efficacy at bladder relaxation based on our data, suggesting a β3AR agonist combined with a nonselective M2/M3 antagonist as the optimal combination therapy in humans.

In conclusion, we described the pharmacology of a new potent and selective β3AR agonist, vibegron, and mechanistic interplay between β3AR agonists and muscarinic antagonists in urinary bladder. We also demonstrated that circulating glycerol and free fatty acid levels could potentially be used as surrogate pharmacodynamic readouts to predict bladder effects of vibegron, although care must be exercised when comparing pharmacodynamic effects in different tissue beds (Morgan et al., 2012; Cook et al., 2014). The potential for β3AR agonists as monotherapy to effectively treat OAB has been validated with the recent approval of mirabegron, but given that both muscarinic and β3ARs play a critical role in bladder

### Table 4

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>0.003</th>
<th>0.01</th>
<th>0.03</th>
<th>0.1</th>
<th>0.3</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/kg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vehicle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tolterodine</td>
<td>0.003</td>
<td>4.1 ± 3.5</td>
<td>18.0 ± 5.7</td>
<td>27.3 ± 5.1</td>
<td>33.9 ± 9.5</td>
<td>31.3 ± 5.0</td>
<td>55.9 ± 18.5</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td>26.7 ± 4.9</td>
<td>31.0 ± 6.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>35.5 ± 9.3</td>
<td>36.4 ± 4.0</td>
<td>43.4 ± 6.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>40.3 ± 9.8&quot;</td>
<td>62.9 ± 8.3</td>
<td>56.8 ± 8.1</td>
<td>69.6 ± 14.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darifenacin</td>
<td>0.003</td>
<td>8.9 ± 7.1&quot;</td>
<td>13.7 ± 4.0</td>
<td>23.7 ± 3.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td>18.3 ± 8.6&quot;</td>
<td>37.1 ± 9.4</td>
<td>43.3 ± 12.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>29.4 ± 8.9&quot;</td>
<td>58.0 ± 19.5</td>
<td>68.7 ± 20.9</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Data from previous publication (Nagabukuro et al., 2011)
function, additional efficacy (with potential for an improved adverse effects profile) may be achieved by combining standard of care antimuscarinics with $\beta_2$AR agonists. Our observations indicate that combination of $\beta_2$AR agonists with dual M2 and M3 antagonists rather than selective M3 antagonists provides optimal efficacy in the treatment of OAB. Our hypothetical translation to the clinic has yet to be determined, but we propose this potential therapeutic approach to redefine the standard of care for the pharmacological treatment of OAB.

Authorship Contributions


Wrote or contributed to the writing of the manuscript: Di Salvo, Nagabukuro, Edmondson, and Struthers.

References


Address correspondence to: Jerry Di Salvo, Evotec USA, 303B College Road East, Princeton, NJ 08540. E-mail: jerry.disalvo@evotec.com